Screen, Notify, See, and Treat: Initial Results of Cervical Cancer Screening and Treatment in Rwanda
- PMID: 33929873
- PMCID: PMC8162968
- DOI: 10.1200/GO.20.00147
Screen, Notify, See, and Treat: Initial Results of Cervical Cancer Screening and Treatment in Rwanda
Abstract
Purpose: To describe the first year results of Rwanda's Screen, Notify, See, and Treat cervical cancer screening program, including challenges encountered and revisions made to improve service delivery.
Methods: Through public radio broadcasts, meetings of local leaders, church networks, and local women's groups, public awareness of cervical cancer screening opportunities was increased and community health workers were enlisted to recruit and inform eligible women of the locations and dates on which services would be available. Screening was performed using human papillomavirus (HPV) DNA testing technology, followed by visual inspection with acetic acid (VIA), and cryotherapy, biopsy, and surgical treatment for those who tested HPV-positive. These services were provided by five district hospitals and 15 health centers to HIV-negative women of age 35-45 and HIV-positive women of age 30-50. Service utilization data were collected from the program's initiation in September 2013 to October 2014.
Results: Of 7,520 cervical samples tested, 874 (11.6%) screened HPV-positive, leading 780 (89%) patients to undergo VIA. Cervical lesions were found in 204 patients (26.2%) during VIA; of these, 151 were treated with cryoablation and 15 were referred for biopsies. Eight patients underwent complete hysterectomy to treat advanced cervical cancer. Challenges to service delivery included recruitment of eligible patients, patient loss to follow-up, maintaining HIV status confidentiality, and efficient use of consumable resources.
Conclusion: Providing cervical cancer screening services through public health facilities is a feasible and valuable component of comprehensive women's health care in resource-limited settings. Special caution is warranted in ensuring proper adherence to follow-up and maintaining patient confidentiality.
Conflict of interest statement
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (
No potential conflicts of interest were reported.
Figures
References
-
- Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013. http://globocan.iarc.fr
-
- Denny L.Cervical cancer treatment in Africa Curr Opin Oncol 23469–4742011 - PubMed
-
- Jemal A, Bray F, Center MM, et al. Global cancer statistics CA Cancer J Clin 6169–902011 - PubMed
-
- Forouzanfar MH, Foreman KJ, Delossantos AM, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: A systematic analysis Lancet 3781461–14842011 - PubMed
-
- Beaulieu N, Bloom D, Bloom R, et al. Breakaway: The global burden of cancer—Challenges and opportunities. A report from the Economist Intelligence Unit. 2009 http://graphics.eiu.com/upload/eb/EIU_LIVESTRONG_Global_Cancer_Burden.pdf
